Dynamical signature of a stellar bulge in a quasar host galaxy at z≃6z\simeq 6

We present a dynamical analysis of a quasar-host galaxy at $z\simeq 6$ (SDSS J2310+1855) using a high-resolution ALMA observation of the [CII] emission line. The observed rotation curve was fitted with mass models that considered the gravitational contribution of a thick gas disc, a thick star-forming stellar disc, and a central mass concentration, which is likely due to a combination of a spheroidal component (i.e. a stellar bulge) and a supermassive black hole (SMBH). The SMBH mass of $5\times 10^9\ \rm M_{\odot}$, previously measured using the CIV and MgII emission lines, is not sufficient to explain the high velocities in the central regions. Our dynamical model suggests the presence of a stellar bulge with a mass of $\rm M_{bulge}\sim 10^{10}\ \rm M_{\odot}$ in this object, when the Universe was younger than 1 Gyr. To finally be located on the local $M_{\rm SMBH}-M_{\rm bulge}$ relation, the bulge mass should increase by a factor of $\sim$40 from $z=6$ to 0, while the SMBH mass should grow by a factor of 4 at most. This points towards asynchronous galaxy-BH co-evolution. Imaging with the JWST will allow us to validate this scenario.Comment: 8 pages, 4 figures, 3 tables. Accepted by A&

Role of cerebrospinal fluid biomarkers to predict conversion to dementia in patients with mild cognitive impairment: a clinical cohort study

Abstract Background: Cerebrospinal fluid (CSF) levels assessment of Aβ1-42 and Tau proteins may be accurate diagnostic biomarkers for the differentiation of preclinical Alzheimer's disease (AD) from age-associated memory impairment, depression and other forms of dementia in patients with mild cognitive impairment (MCI). The aim of our study was to explore the utility of CSF biomarkers in combination with common cognitive markers as predictors for the risk of AD development, and other forms of dementia, and the time to conversion in community patients with MCI. Methods: A group of 71 MCI patients underwent neurological assessment, extended neuropsychological evaluation, routine blood tests, ApoE determination, and lumbar puncture to dose t-tau, p-tau181, Aβ1-42. We investigated baseline CSF and neuropsychological biomarker patterns according to groups stratified with later diagnoses of AD conversion (MCI-AD), other dementia (MCI-NAD) conversion, or clinical stability (sMCI). Results: Baseline Aβ1-42 CSF levels were significantly lower in MCI-AD patients compared to both sMCI and MCI-NAD. Additionally, p-tau181 was higher in the MCI-AD group compared to sMCI. The MCI-AD subgroup analysis confirmed the role of Aβ1-42 in its predictive role of time to conversion: rapid converters had lower Aβ1-42 levels compared to slow converters. Logistic regression and survival analysis further supported the key predictive role of baseline Aβ1-42 for incipient AD and dementia-free survival. Conclusions: Our results confirm the key role of CSF biomarkers in predicting patient conversion from MCI to dementia. The study suggests that CSF biomarkers may also be reliable in a real world clinical setting

Platelet Function Testing in Patients with Acute Ischemic Stroke: An Observational Study

Background: The measurement of platelet reactivity in patients with stroke undergoing antiplatelet therapies is not commonly performed in clinical practice. We assessed the prevalence of therapy responsiveness in patients with stroke and further investigated differences between patients on prevention therapy at stroke onset and patients naive to antiplatelet medications. We also sought differences in responsiveness between etiological subtypes and correlations between Clopidogrel responsiveness and genetic polymorphisms. Methods: A total of 624 stroke patients on antiplatelet therapy were included. Two different groups were identified: "non-naive patients", and "naive patients". Platelet function was measured with multiple electrode aggregometry, and genotyping assays were used to determine CYP2C19 polymorphisms. Results: Aspirin (ASA) responsiveness was significantly more frequent in naive patients compared with non-naive patients (94.9% versus 82.6%, P < .0010). A better responsiveness to ASA compared with Clopidogrel or combination therapy was found in the entire population (P < .0010), in non-naive patients (P < .0253), and in naive patients (P < .0010). Multivariate analysis revealed a strong effect of Clopidogrel as a possible "risk factor" for unresponsiveness (odds ratio 3.652, P < .0001). No difference between etiological subgroups and no correlations between responsiveness and CYP2C19 polymorphisms were found. Conclusion: In our opinion, platelet function testing could be potentially useful in monitoring the biological effect of antiplatelet agents. A substantial proportion of patients with stroke on ASA were "resistant", and the treatment with Clopidogrel was accompanied by even higher rates of unresponsiveness. Longitudinal studies are needed to assess whether aggregometry might supply individualized prognostic information and whether it can be considered a valid tool for future prevention strategies

CYP1A1 Variability In Human Populations

The human cytochrome P4501A1 (CYP1A1) enzyme plays an important role in the metabolism of xenobiotics and endogenous substrates. Because polymorphisms within the CYP1A1 gene have been shown to be associated with various cancer risks and with the predicting clinical efficacy of some chemotherapies in different populations, most studies focus on their clinical significance. We, however, were interested in evaluating whether the polymorphisms could be used to distinguish human populations. Four single nucleotide CYP1A1 polymorphisms (rs4646903/ g.75011641; rs1048943/g.75012985; g.75012235; and rs1799814/ g.75012987) were analysed via PCR-RFLP assay in 1,195 individuals of various human groups from all over the world. In order to gain a more complete view of the genetic variability of the CYP1A1 gene, different statistical analyses were performed upon the populations of the present study and upon the limited data gleaned from previously studied populations. The allele and haplotype frequencies vary among populations: the rs4646903 (C) and rs1048943 (G) have been found to be nearly always linked and were found at the highest frequencies in Native Americans, while the variant associated to the position g.75012235 was only detected in certain African populations. Our work clearly indicates that the CYP1A1 polymorphisms differ among populations and that the prediction of genotypes constitutes an important aspect of precision medicine since some variants were associated with certain cancers and rs1048943 show strong association with optimized chemotherapy. Moreover, the CYP1A1 gene plays an important role in the metabolism of xenobiotics and it is likely that its frequencies could be strongly influenced by environmental factors

Biomolecular NMR at 1.2 GHz

The development of new superconducting ceramic materials, which maintain the superconductivity at very intense magnetic fields, has prompted the development of a new generation of highly homogeneous high field magnets that has trespassed the magnetic field attainable with the previous generation of instruments. But how can biomolecular NMR benefit from this? In this work, we review a few of the notable applications that, we expect, will be blooming thanks to this newly available technology.Comment: 17 pages, 13 figure

Pattern of care and effectiveness of treatment for glioblastoma patients in the real world: Results from a prospective population-based registry. Could survival differ in a high-volume center?

BACKGROUND: As yet, no population-based prospective studies have been conducted to investigate the incidence and clinical outcome of glioblastoma (GBM) or the diffusion and impact of the current standard therapeutic approach in newly diagnosed patients younger than aged 70 years. METHODS: Data on all new cases of primary brain tumors observed from January 1, 2009, to December 31, 2010, in adults residing within the Emilia-Romagna region were recorded in a prospective registry in the Project of Emilia Romagna on Neuro-Oncology (PERNO). Based on the data from this registry, a prospective evaluation was made of the treatment efficacy and outcome in GBM patients. RESULTS: Two hundred sixty-seven GBM patients (median age, 64 y; range, 29-84 y) were enrolled. The median overall survival (OS) was 10.7 months (95% CI, 9.2-12.4). The 139 patients 64aged 70 years who were given standard temozolomide treatment concomitant with and adjuvant to radiotherapy had a median OS of 16.4 months (95% CI, 14.0-18.5). With multivariate analysis, OS correlated significantly with KPS (HR = 0.458; 95% CI, 0.248-0.847; P = .0127), MGMT methylation status (HR = 0.612; 95% CI, 0.388-0.966; P = .0350), and treatment received in a high versus low-volume center (HR = 0.56; 95% CI, 0.328-0.986; P = .0446). CONCLUSIONS: The median OS following standard temozolomide treatment concurrent with and adjuvant to radiotherapy given to (72.8% of) patients aged 6470 years is consistent with findings reported from randomized phase III trials. The volume and expertise of the treatment center should be further investigated as a prognostic factor

lelli,bandini, luccaroni, rinaldi, casarini, magazè scuola ORA (BZ) innesti grafting. Padiglione Italia. 14. Mostra Internazionale di architettura. La Biennale di Venezia

Progetto architettonico Scuola elementare di ORA (BZ) Catalogo delle opere invitate al Padiglione Italia La biennale di Venezia. 14. Mostra internazionale di architettura

lelli,bandini, luccaroni, rinaldi, casarini, magazè scuola ORA (BZ) innesti grafting. Padiglione Italia. 14. Mostra Internazionale di architettura. La Biennale di Venezia

Progetto architettonico Scuola elementare di ORA (BZ) Catalogo delle opere invitate al Padiglione Italia La biennale di Venezia. 14. Mostra internazionale di architettura

Progetto complesso scolastico ad ORA Bolzano [La Biennale di Venezia - mostra internazionale di architettura - Padiglione Italia INNESTI GRAFTING]

Il progetto del complesso scolastico di Ora a Bolzano è stata scelta per l'esposizione Innesti Grafting Padiglione italiano alla Biennale di Venezia mostra internazionale di architettura del 2014. La ricerca di un edificio sostenibile a bassissimo consumo energetico e contemporaneamente, completamente inserito nel delicato tessuto urbano storico di Ora (BZ), è la motivazione della scelta di quest'opera. Il curatore della Mostra è il Prof. Cino Zucchi

Opera di Architettura "Residenze Via Padovani, Imola Bo"

Progetto e realizzazione di un'opera di architettura come rigenerazione del tessuto della periferia attraverso il rapporto spazio pubblico e spazio privato. Prototipo di residenza a costi contenuti e ad alta qualità ambientale. Opera è stata apprezzata dalla critica e da esperti internazionali per la qualità ambientale raggiunta con pochi mezzi e l'utilizzo di artigianato locale. Considerato un esempio di riqualificazione delle periferie attraverso la cellula base della città: la casa di abitazione. I materiali naturali e la composizione architettonica sviluppano il tema della solida leggerezza del costruire. Il meccanismo progettuale sfrutta una forma strutturale semplice che permette una profonda "facciata libera" a greca. La presenza del vicino parco storico ha suggerito per quest'area periferica priva di riferimenti il forte legame al tessuto connettivo verde, dentro il quale sono inseriti i due corpi di fabbrica. Le soluzioni tecnologiche tendono a far scomparire gli elementi architettonici riducendoli a spessori sottili come fogli